New drugs: asenapine, iloperidone, and bepotastine besilate.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
Abbas
Cheryl A
CA
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003233:Conjunctivitis, Allergic / Q000188:drug therapy; D003986:Dibenzocycloheptenes; D017277:Drug Approval; D004348:Drug Labeling; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D055815:Young Adult
D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; D006633:Histamine Antagonists; D007555:Isoxazoles; D010880:Piperidines; D011725:Pyridines; C511534:bepotastine besilate; C522667:asenapine; C081732:iloperidone